IGF2BP2 (also known as Imp2) activates the PI3K/Akt signaling pathway and thereby promotes glioma progression, whereas its inhibition sensitizes glioma cells to temozolomide treatment (Mu et al., 2015). The gene discussed is IGF2BP2; the disease is glioma.